Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: A dermatology expert group consensus

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 3, 2012, Pages 373-381

  Langley, R G ^a   Saurat, J H ^b   Reich, K ^c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c DERMATOLOGIKUM HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIPSORIASIS AGENT; BETAMETHASONE; CALCIPOTRIOL; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; FLUOROURACIL; FUMARIC ACID DIMETHYL ESTER; INFLIXIMAB; METHOTREXATE; NIMESULIDE; RETINOID; TAZAROTENE;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONSENSUS; DELPHI STUDY; DERMATOLOGIST; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; NAIL DISEASE; NAIL PSORIASIS QOL SCALE; NAIL PSORIASIS SEVERITY INDEX; PHOTOCHEMOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS SEVERITY INDEX; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; SYSTEMIC THERAPY; TREATMENT PLANNING;

CANADA; DELPHI TECHNIQUE; DISEASE MANAGEMENT; EUROPE; HUMANS; NAIL DISEASES; PHYSICIAN'S PRACTICE PATTERNS; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 84857373288     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04349.x     Document Type: Article

References (22)

1. Jiaravuthisan MM, Dasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57: 1-27. (Pubitemid 46899261)
2. Lawry M. Biological therapy and nail psoriasis. Dermatol Ther 2007; 20: 60-67. (Pubitemid 46568378)
3. de Jong EM, Seegers BA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology 1996; 193: 300-303.
4. McGonagle D, Tan AL, Benjamin M. The nail as a musculoskeletal appendage-implications for an improved understanding of the link between psoriasis and arthritis. Dermatology 2009; 218: 97-102.
5. Rich P, Scher R. Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49: 206-212. (Pubitemid 36951265)
6. Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 2003; 25: 2487-2505. (Pubitemid 37373927)
7. Augustin M, Reich K, Blome C, et al. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 2010; 163: 580-585.
8. Langley RG, Daudén E. Treatment and management of psoriasis with nail involvement: a focus on biologic therapy. Dermatology 2010; 221 (Suppl. 1): 29-42.
9. Linstone HA, Turoff M, eds. The Delphi Method: Techniques and Applications. Addison-Wesley, Reading, MA, 1975: 291-321.
10. Rauch W. The decision Delphi. Technol Forecast Soc Change 1979; 15: 159-169.
11. Rowe HI. The 'Collaborative' Delphi symposium. Annual Sustainable Rangelands Roundtable Meeting; 2005; Phoenix, AZ, USA.
12. Bianchi L, Bergamin A, de Felice C, et al. Remission and time of resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol 2005; 52: 736-737. (Pubitemid 40585474)
13. Rich P, Griffiths CE, Reich K, et al. Baseline nail disease in patients with moderate-to-severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008; 58: 224-231.
14. Reich K, Nestle F, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374. (Pubitemid 41443403)
15. Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008; 35: 869-876. (Pubitemid 351747130)
16. Van den Bosch F, Reece R, Behrens F, et al. Clinically important nail psoriasis improvements are achieved with adalimumab (Humira): results from a large open-label prospective study (STEREO). Ann Rheum Dis 2007; 66 (Suppl. II): 421.
17. de Berker D. Management of nail psoriasis. Clin Exp Dermatol 2000; 25: 357-362.
18. Taieb C, Myon E, Voisard JJ, et al. Nail psoriasis: epidemiological study in France. EADV 2005. Poster P16.37.
19. Reich K. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 1): 15-21.
20. Scher RK. Psoriasis of the nail. Dermatol Clin 1985; 3: 387-394. (Pubitemid 15017620)
21. Gladman DD, Antoni C, Mease PJ, et al. Psoriatic arthritis: epidemiology, clinical features, course and outcome. Ann Rheum Dis 2005; 64 (suppl II): ii14-ii17. (Pubitemid 40288513)
22. Ortonne JP, Baran R, Corvest M, et al. Development and validation of nail psoriasis quality of life scale (NPQ10). J Eur Acad Dermatol Venereol 2010; 24: 22-27.